CClinicalTrials.gg
CompletedNCT00602927Updated May 10, 2011Results posted

Effects of Varenicline on Brain Activity During Nicotine Abstinence

An interventional study of Varenicline and Placebo in Nicotine Dependence, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-10.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This project aims to define mechanisms through which varenicline might be an effective smoking cessation medication.

Read the detailed description

Thirty treatment seeking smokers will be recruited to complete a 40-day within-subject (cross-over), double-blind study that will assess effects of varenicline on brain activation while performing certain tasks. Prior to beginning the study, participants will complete an health and physical screening to determine final eligibility. Following a medication run-up and a 3.5 day abstinence period, participants will complete study period 1 (an fMRI scan while performing attention, working memory and emotion tasks). After a 14 to 21-day washout period the study procedures will be repeated with placebo (order of study medication counterbalanced). After completion of both study periods, all participants will be offered a 13-week quit smoking program with varenicline.

02

Conditions studied

  • Nicotine Dependence

Browse trials for

Keywords

  • Varenicline, Imaging, fMRI
03

In context

Tobacco Use Disorder

968 studies on the registry are indexed under Tobacco Use Disorder; 126 are open to participants now.

This study's enrollment of 38 is below the median of 89 across 851 interventional studies indexed under Tobacco Use Disorder.

Browse Tobacco Use Disorder studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Treatment-seeking smokers between the ages of 18 and 65, that smoke at least 10 cigarettes/day for at least the past 6 months
  2. Provide a baseline CO (carbon monoxide) reading of >10ppm
  3. Provide written informed consent and are fluent, English-speaking
  4. Weight of equal to or less than 300 lbs

Exclusion criteria

Exclusion Criteria:

Smoking Behavior

  1. Use of chewing tobacco, snuff or cigars
  2. Current enrollment or plans to enroll in another smoking cessation program in the next 5 months
  3. Plan to use other nicotine substitutes or smoking cessation treatments in the next 5 months
  4. Provide a baseline CO (carbon monoxide) reading ≤10 ppm

Alcohol/Drug Exclusion Criteria

  1. History of substance abuse and/or currently receiving treatment for substance abuse
  2. Current alcohol consumption that exceeds 25 standard drinks/week
  3. A breath alcohol concentration reading ≥ 0.01 at the H\&P (health \& physical) screening or either of the lab sessions

Medication Exclusion Criteria

  1. Prior use of Chantix
  2. Current use or recent discontinuation (within last 14-days) of the following medications:

    1. Any form of smoking cessation medication
    2. Any form of anti-psychotic medications that includes:

      • antipsychotics,
      • atypical antipsychotics,
      • mood-stabilizers,
      • anti-depressants (tricyclic, SSRI, MAOI),
      • anti-panic agents,
      • anti-obsessive agents,
      • anti-anxiety agents, and
      • stimulants (e.g., Provigil, Ritalin)
      • herbal medications (St. John's Wort)
    3. Opioid medication for chronic pain
    4. Anti-coagulants
    5. Any heart medications
    6. Daily medication for asthma

Medical Exclusion Criteria

  1. Women who are pregnant, planning a pregnancy, or lactating;
  2. History or current diagnosis of psychosis, current major depression, bipolar disorder, ADHD, schizophrenia, or any Axis 1 disorder as identified by the MINI
  3. Serious or unstable disease within the past 6 months (heart disease, HIV)
  4. Diagnosis of cancer in the past 6 months or if successful treatment for cancer has not ended within the past 6 months
  5. History of epilepsy or a seizure disorder
  6. History or current diagnosis (last 6-months) of abnormal rhythms and/or tachycardia (>100 beats/minute); history or current diagnosis of COPD (chronic obstructive pulmonary disease), cardiovascular disease (stroke, angina, coronary heart disease), heart attack in the last 6 months, uncontrolled hypertension (SBP>150 or DBP>90)
  7. History of kidney and/or liver failure (including transplant)
  8. History of head trauma or prior seizure; family history of a seizure disorder, brain (or central nervous system) tumor
  9. Use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for MRI (magnetic resonance imaging);
  10. Low or borderline intellectual functioning - determined by receiving a score \<80 on the Shipley verbal IQ Test
  11. Non-English speaking; determined at phone screen
  12. History of claustrophobia (contraindicated for MRI) or color blindness (task requires color recognition); self-report at telephone screen
  13. Being left-handed
  14. Any fore-limb deformity
  15. Wearing cochlear implant or bi-lateral hearing aids

General Exclusion

  1. Any medical condition or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and/or Study Physician.
  2. Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician.
  3. Any physical or visual impairment that may prevent the individual from using a computer keyboard or completing any study tasks.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Varenicline

    Drug: Varenicline

Interventions

  • DrugVarenicline

    Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily

    Also known as: Chantix

  • DrugPlacebo

    Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.

06

What researchers measure

Primary outcomes

  1. Percent Change BOLD Signal

    We calculated the percent BOLD signal change while performing the N-back task between the varenicline vs. placebo session. We subtracted BOLD signal observed during the 0-back condition from the BOLD signal observed during the 3-back condition (3back minus 0-back)We controlled for relevant co-variates such as sex, nicotine dependence level and education.

    Time frame: Day 13

Secondary outcomes

  1. Effect of Varenicline Treatment on Task Performance (N-back Correct Response Time)

    We examined the difference in correct reaction time on the N-back task between varenicline and placebo treatment. Models included terms for the main effect of treatment period (varenicline vs. placebo), memory load (0-back, 1-back, 2-back, 3-back) and covariates. We tested for interactions between nicotine dependence severity and treatment.

    Time frame: Day 13

07

Results

Posted May 2, 2011

Participant flow

Participants were recruited from mass media advertising in the greater Philadelphia area from November 2007 - June 2008.

Period 1: 13 Days
Participant flow — Period 1: 13 Days
MilestonePlacebo First, Then VareniclineVarenicline First, Then Placebo
Started1919
Completed1514
Not completed45
Withdrew: Protocol violation24
Withdrew: Mri scanner technical issue10
Withdrew: Time10
Withdrew: Claustrophobia01
Period 2: 14 Days
Participant flow — Period 2: 14 Days
MilestonePlacebo First, Then VareniclineVarenicline First, Then Placebo
Started1514
Completed1512
Not completed02
Withdrew: Protocol violation02
Period 3: 13 Days
Participant flow — Period 3: 13 Days
MilestonePlacebo First, Then VareniclineVarenicline First, Then Placebo
Started1512
Completed139
Not completed23
Withdrew: Protocol violation01
Withdrew: Mri data quality22

Outcome measures

PrimaryPercent Change BOLD Signal

We calculated the percent BOLD signal change while performing the N-back task between the varenicline vs. placebo session. We subtracted BOLD signal observed during the 0-back condition from the BOLD signal observed during the 3-back condition (3back minus 0-back)We controlled for relevant co-variates such as sex, nicotine dependence level and education.

Time frame:
Day 13
Reported as:
Mean · BOLD Signal Change (3-back minus 0-back)
Percent Change BOLD Signal
BOLD Signal Change (3-back minus 0-back)PlaceboVarenicline
Percent Change BOLD Signal0.48 ± 0.050.61 ± 0.03
SecondaryEffect of Varenicline Treatment on Task Performance (N-back Correct Response Time)

We examined the difference in correct reaction time on the N-back task between varenicline and placebo treatment. Models included terms for the main effect of treatment period (varenicline vs. placebo), memory load (0-back, 1-back, 2-back, 3-back) and covariates. We tested for interactions between nicotine dependence severity and treatment.

Time frame:
Day 13
Reported as:
Mean · Milliseconds
Effect of Varenicline Treatment on Task Performance (N-back Correct Response Time)
MillisecondsPlaceboVarenicline
Effect of Varenicline Treatment on Task Performance (N-back Correct Response Time)692.14 ± 128.57637.99 ± 164.30

Adverse events

Collected over Day 13. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo First, Then Varenicline—0/19 (0%)0/19 (0%)
Varenicline First, Then Placebo—0/19 (0%)1/19 (5.3%)
Most frequent other events
Most frequent other events
EventPlacebo First, Then VareniclineVarenicline First, Then Placebo
Severe LethargyGeneral disorders0/191/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo First, Then VareniclineVarenicline First, Then PlaceboTotal
<=18 years000
Between 18 and 65 years191938
>=65 years000
Age Continuous
Age Continuous(years)Placebo First, Then VareniclineVarenicline First, Then PlaceboTotal
Mean41.05 ± 13.3239.79 ± 12.6840.42 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)Placebo First, Then VareniclineVarenicline First, Then PlaceboTotal
Female91019
Male10919
Region of Enrollment
Region of Enrollment(participants)Placebo First, Then VareniclineVarenicline First, Then PlaceboTotal
United States191938
08

Study locations

1 site
  • Tobacco Use Research Center
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry. 2010 Apr 15;67(8):715-21. doi: 10.1016/j.biopsych.2010.01.016. Epub 2010 Mar 6. PubMed 20207347 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00602927
Lead sponsor
University of Pennsylvania
Collaborators
Pfizer, National Cancer Institute (NCI)
First posted
Jan 28, 2008
Start date
Nov 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
May 2, 2011
Last update
May 10, 2011

Study contacts

Caryn Lerman, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion